

T: 0131-244-2528  
E: irene.fazakerley@gov.scot

**URGENT MESSAGE TO:**

1. Directors of Pharmacy
2. Medical Directors NHS Boards

28 July 2021

Dear Healthcare Professional,

**COVID THERAPEUTIC ALERT – PAVILIZUMAB PASSIVE IMMUNISATION AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) IN PRE-TERM INFANTS**

Please see attached UK CMO letter and rapid policy statement, which extends eligibility for palivizumab beyond the guidance issued by the Joint Committee on Vaccination and Immunisation (JCVI), specifically in the context of the COVID-19 pandemic, has now been updated to accommodate the atypical current seasonal pattern of infection and increase the maximum number of doses from five to seven for onward transmission as detailed below:-

Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors arrange to forward this alert on to:-

- General Practitioners
- Accident & Emergency Departments
- Nurses
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

**IRENE FAZAKERLEY**  
**Medicines Policy Team**